OST催化子单元的冗余性使得N-糖化的治疗向成为可能
Marta Baro1, Hojin Lee1, Vanessa Kelley1,2
1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, 06510 USA.
bioRxiv : the preprint server for biology
|December 16, 2024
概括
使用像NGI-189这样的寡糖转移酶 (OST) 抑制剂向蛋白质N-糖化,对瘤学有很大的前景. 这种方法在没有引起毒性的肺癌异种移植中有效抑制EGFR,提供了一种新的治疗途径.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 蛋白N-糖化对细胞表面受体功能至关重要,包括EGFR.
- 从历史上看,N-糖化酶的本质限制了其在癌症中的治疗向.
- 哺乳动物的寡糖转移酶 (OST) 具有催化子单元对应物STT3A和STT3B,具有选择性抑制的潜力.
研究的目的:
- 探索OST抑制剂的化学生物学,以针对性地抑制N-糖基化.
- 开发一种有限的N-糖化抑制策略,以影响EGFR信号传递.
- 识别和评估具有瘤学治疗潜力的新型OST抑制剂.
主要方法:
- 针对STT3A或STT3B的小分子的合成和表征,具有改善的药理动力学.
- 在体外评估OST抑制剂活性和选择性.
- 在患者衍生和TKI耐药EGFR突变肺癌异种移植模型中对化合物的体内测试.
主要成果:
- 开发出具有药理动力学特性和对STT3A或STT3B的选择性的小分子.
- 在异种移植模型中,化合物NGI-189在减少瘤生长或导致回归方面表现出有效性.
- 在临床前模型中,NGI-189没有表现出可观察到的毒性.
结论:
- 可生物利用的OST抑制剂可以被开发为瘤学的有效治疗剂.
- 向抑制N-糖基化是一种可行的策略,用于治疗EGFR突变肺癌,包括耐TCI的形式.
- NGI-189代表了在癌症治疗中进一步临床开发的有希望的候选药物.
更多相关视频
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
8.6K
09:54Identification and Characterization of Protein Glycosylation using Specific Endo- and Exoglycosidases
Published on: December 26, 2011
36.6K
相关概念视频
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
Export of Misfolded Proteins out of the ER
3.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.5K
Protein Folding Quality Check in the RER
3.7K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
3.7K
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Protein Modifications in the RER
5.0K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.0K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
